KRAS and cancer: Although insensitive to GAP-assisted hydrolysis, KRAS-mutated oncoproteins have measurable intrinsic GTP hydrolysis rates, could cycle between their active and inactive states in cancer cells, and are dependent on nucleotide exchange for activation [20].